ATM and breast cancer: To confirm that the observed treatment effect is due to combined EZH2/ATM inhibition and not caused by any potential off-target effect, BRCA1-deficient and -proficient mouse mammary tumor cells were treated with the structurally distinct EZH2 and ATM inhibitors ZLD1039 [36] and KU60019 [31], respectively (Fig. 4C, D).